VCYT Q2 2024 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$114M+26.7% YoY

Gross Profit

$78M68.1% margin

Operating Income

$5M4.0% margin

Net Income

$6M5.0% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

+18.2%

Cash Flow

Operating Cash Flow

$30M

Free Cash Flow

$27M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$102M

Stockholders' Equity

$1.1B

Cash & Equivalents

$236M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$114M	$90M	+26.7%
Gross Profit	$78M	$56M	+39.6%
Operating Income	$5M	-$8M	+157.2%
Net Income	$6M	-$8M	+168.2%

Revenue Segments

Testing

$107M93%

Product

$4M3%

Biopharmaceutical And Other

$4M3%